Veranova is a global leader in the development and manufacturing of specialist and complex active pharmaceutical ingredients (APIs) for pharma and biotech customers.
Synthesis of complex molecules including linker/payloads, TPDs/PROTACs, PEGs/lipids, peptides and oligonucleotides.
Expertise in highly regulated drug substances requiring special handling and controls including HPAPIs and controlled substances.
of FDA-approved small molecule drugs since 2014 have collaborated with us
active Drug Master Files (DMFs) to date
completed solid form projects across a range of structurally diverse and complex APIs
Discover new ways to advance your science with Veranova. Our capabilities span a wide range of development technologies and specialties—all backed by comprehensive industry knowledge and experience.
Extensive capabilities across both process and analytical development.
Tech capabilities that encompass solid form sciences including crystallization development and particle engineering.
Specialty capabilities include highly potent APIs and drug linkers in addition to complex small molecule chemistry.
Whether you need a partner in development or an experienced leader to navigate complex scale-up, Veranova can help. Our deep knowledge of API manufacturing and processes is supported by a collaborative, consultative approach to ensure your expectations and milestones are met.
With deep technical expertise and impressive flexibility, we help develop solutions and processes that support innovation.
To support clinical trials, we establish manufacturing processes and analytical methods that are scalable and collaborative.
We efficiently manage manufacturing APIs in commercial quantities with our agile network and supply chain.
We help you optimize your manufacturing processes and scale-up your services with confidence, speed and flexibility.
We were honored to welcome Nobel Prize laureate, Professor of Chemistry at Stanford University, and Veranova Advisory Board member, Carolyn Bertozzi to our SCALE 2025 Symposium event in July.
Listen to Carolyn’s talk where she discusses her decades-long work developing bioorthogonal and click chemistries, and how these innovations are enabling the construction of complex therapeutic modalities across pharma today.
Read our latest white paper highlighting critical analytical techniques necessary for the characterization of ADCs, emphasizing their physicochemical properties, biological activity, stability assessments, and regulatory implications.
In recent years, interest in psychedelics for therapeutic use has increased. Among these is psilocybin, the world’s most studied psychedelic compound for the treatment of mental health conditions. This Expert Insight explores the potential of this molecule, and the challenges associated with synthesizing it at scale.
Discover new ways to advance your science with Veranova.
Contact us